Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics

Spectinamides 1599 and 1810 are lead spectinamide compounds currently under preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. These compounds have previously been tested at various combinations of dose level, dosing frequency, and route of...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Keyur R., Lukka, Pradeep B., Wagh, Santosh, Temrikar, Zaid H., Liu, Jiuyu, Lee, Richard E., Braunstein, Miriam, Hickey, Anthony J., Robertson, Gregory T., Gonzalez-Juarrero, Mercedes, Edginton, Andrea, Meibohm, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305115/
https://www.ncbi.nlm.nih.gov/pubmed/37376207
http://dx.doi.org/10.3390/pharmaceutics15061759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305115/
https://www.ncbi.nlm.nih.gov/pubmed/37376207
http://dx.doi.org/10.3390/pharmaceutics15061759

Ejemplares similares